Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hany Jacob

Critical Care Medicine Maumee, OH Medical Doctor

NPI 1992786677 CMS profile 135270

1661 Holland Rd Ste 100, Maumee, OH 43537

Open in the dashboard

General payments

$6,292

319 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hany Jacob of Maumee, OH is reported in the CMS Open Payments database as having received $6,292 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,129 46
2024 General $1,014 44
2023 General $1,303 59
2022 General $625 38
2021 General $762 42
2020 General $440 29
2019 General $1,019 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hany Jacob
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Hany Jacob were reported at $1,129. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Hany Jacob Critical Care Medicine median Middle half National median
2019 $1,019 $149 $51–$535 $163
2020 $440 $110 $30–$325 $114
2021 $762 $125 $34–$403 $132
2022 $625 $157 $49–$582 $149
2023 $1,303 $162 $56–$621 $160
2024 $1,014 $168 $53–$634 $164
2025 $1,129 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,156 58 payments
  2. GlaxoSmithKline, LLC. $978 46 payments
  3. United Therapeutics Corporation $437 25 payments
  4. Regeneron Healthcare Solutions, Inc. $419 13 payments
  5. Insmed, Inc. $376 17 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $288 17 payments
  7. Actelion Pharmaceuticals US, Inc. $275 13 payments
  8. Genzyme Corporation $250 11 payments
  9. Harmony Biosciences LLC $233 13 payments
  10. Mylan Specialty L.P. $216 8 payments
  11. Other $1,664 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,200 317 payments
  2. Education $91 2 payments
Products named General payments · program years 2019–2025
  1. BREZTRI $436 18 payments
  2. Arikayce $376 17 payments
  3. TEZSPIRE $366 18 payments
  4. AREXVY $346 7 payments
  5. DUPIXENT $311 7 payments
  6. TRELEGY ELLIPTA $287 23 payments
  7. OPSUMIT $275 13 payments
  8. NUCALA $254 16 payments
  9. ORENITRAM $238 17 payments
  10. TYVASO $237 11 payments
  11. Other $4,111 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,526

Median for Critical Care (Intensivists): 406

Drug cost

$657,994

Median for Critical Care (Intensivists): $197,260

Branded share of claims

72.1%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 274 $227,537
Ambrisentan Generic 13 $83,084
Breo Ellipta Fluticasone/Vilanterol Brand 157 $78,587
Tezspire Tezepelumab-Ekko Brand 15 $61,863
Tadalafil Generic 21 $45,385
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 62 $45,108
Incruse Ellipta Umeclidinium Bromide Brand 58 $19,211
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 126 $17,309
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 30 $16,034
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 28 $13,514

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$126,292

Medicare's payments for the services billed

Medicare patients

377

Average age 73

Services billed

1,868

179 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 58%
Heart failure 56%
Arthritis 55%
Diabetes 53%
Depression 48%
Chronic kidney disease 47%
Ischemic heart disease 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $217
$217 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $60
  • Amgen Inc. $21
$81 15 —
Prolastin-C Liquid
  • Grifols USA, LLC $60
$60 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $59
$59 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record